Menu
Search
|

Menu

Close
X

Ascendis Pharma A/S ASND.OQ (NASDAQ Stock Exchange Global Select Market)

59.75 USD
+1.74 (+3.00%)
As of 8:23 PM GMT
chart
Previous Close 58.01
Open 58.00
Volume 28,110
3m Avg Volume 32,327
Today’s High 60.14
Today’s Low 58.00
52 Week High 76.98
52 Week Low 35.02
Shares Outstanding (mil) 36.37
Market Capitalization (mil) 1,304.09
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 8 analysts

KEY STATS

Revenue (mm, EUR)
FY18
0
FY17
2
FY16
5
FY15
8
EPS (EUR)
FY18
-1.616
FY17
-3.683
FY16
-2.603
FY15
-1.344
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
367.07
5.69
Price to Book (MRQ)
vs sector
7.85
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
0.00
15.71
LT Debt to Equity (MRQ)
vs sector
0.00
11.53
Return on Investment (TTM)
vs sector
-83.31
15.05
Return on Equity (TTM)
vs sector
-83.31
16.62

EXECUTIVE LEADERSHIP

Michael Wolff Jensen
Chairman of the Board, Senior Vice President, General Counsel, Since 2013
Salary: --
Bonus: --
Jan Moeller Mikkelsen
President, Chief Executive Officer, Director, Since 2007
Salary: --
Bonus: --
Scott Smith
Chief Financial Officer, Senior Vice President, Since 2016
Salary: --
Bonus: --
Lotte Soenderbjerg
Senior Vice President, Chief Administrative Officer, Since 2007
Salary: --
Bonus: --
Harald Rau
Senior Vice President, Chief Scientific Officer, Since 2007
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Tuborg Boulevard 5
HELLERUP     2900

Phone:

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.

SPONSORED STORIES